Báo chí nói về chúng tôi

IRVINE, Calif., Jan. 21, 2026 /PRNewswire/ -- Gene Solutions, a global biotechnology company, and Pangea Laboratory, a CLIA-certified, CAP-accredited Next Generation Sequencing (NGS) leader in validation platforms for Laboratory Developed Tests (LDTs), announced a strategic collaboration to advance U.S. verification and clinical validation of liquid biopsy assays designed for cancer detection, profiling, and monitoring.

SINGAPORE, Dec. 20, 2025 /PRNewswire/ -- Gene Solutions, a pioneering genetic testing company, announced key achievements at the European Society for Medical Oncology (ESMO) Asia Congress 2025—held in Singapore on December 5–7. Highlights included a full-house symposium, seven scientific abstracts with two earning Best Poster designations, and meaningful engagement with thousands of oncologists from across the Asia-Pacific region at the company's exhibition booth.

TAIPEI, Nov. 28, 2025 /PRNewswire/ -- Precision medicine is entering a new era, driven by breakthroughs in genetic technology and Artificial Intelligence (AI). Multi-Cancer Early Detection (MCED) has become a global trend, and Taiwan joins this movement with the introduction of SPOT-MAS - an advanced screening solution developed by Gene Solutions, a global leader in precision oncology and genomics, in collaboration with local partner Gene Health.

HONG KONG, Nov. 17, 2025 /PRNewswire/ -- The APAC Precision Oncology Conference 2025, themed Artificial Intelligence (AI) & Multi-omics in Cancer Management, convened in Hong Kong on November 1, marking Lung Cancer Awareness Month with a clear message: AI and multi-omics are no longer theoretical - they are driving real-world advancements in cancer care across the Asia-Pacific (APAC) region.

Raffles Medical Group (the Group) and Gene Solutions have signed a Memorandum of Understanding (MOU) on 22 October 2025 to streamline patient recruitment for oncology clinical trials, marking a significant milestone in advancing precision medicine in Southeast Asia.

At the Singapore Society of Oncology Annual Scientific Meeting 2025 (SSO ASM 2025), Gene Solutions showcased how Molecular Residual Disease (MRD) and AI-powered multi-omics technologies are advancing precision oncology across Asia-Pacific, reinforcing Singapore's role as a hub for innovation and global collaboration.

 Gene Solutions, a leading multinational biotechnology company and Shenzhen USK Bioscience Co., Ltd. (USKBio), a prominent innovator in molecular diagnostics, have entered a strategic partnership through a Memorandum of Understanding (MOU).

Gene Solutions has formalized a strategic collaboration with Zhejiang Shaoxing Topgen Biomedical Technology Co., Ltd., a CAP-accredited laboratory with a well-established footprint across all over China.

Gene Solutions, a pioneer in AI-driven precision oncology hosted K-CONNECT APAC 2025, a pivotal summit uniting over 100 distinguished oncologists and molecular biologists from nine Asia-Pacific countries. — This landmark event marked a significant milestone in advancing precision oncology, fostering collaboration, and driving innovation in the fields of circulating tumor DNA (ctDNA), Molecular Residual Disease (MRD), and Comprehensive Genomic Profiling (CGP).

NEW TAIPEI CITY, May 16, 2025 -- In a groundbreaking move, Gene Solutions, a leader in prenatal and oncology genetic testing, and NEWCL Biomedical Laboratory, Taiwan's pioneering clinical laboratory with LDTs certification, have joined forces to establish an advanced Next-Generation Sequencing (NGS) laboratory in Taiwan. This collaboration was sealed with the signing of a Memorandum of Understanding (MoU) at NEWCL's state-of-the-art facility in New Taipei City.

HO CHI MINH CITY, April 22, 2025 /PRNewswire/ -- Gene Solutions, a leading multinational biotech company specializing in advanced genetic testing, and Element Biosciences, a company democratizing access to advanced life science solutions, have entered into a strategic collaboration. The collaboration was formalized with the signing of a Memorandum of Understanding (MoU) during Element Biosciences' visit to Gene Solutions' laboratory.

SINGAPORE, April 19, 2025 /PRNewswire/ -- Gene Solutions, a biotechnology company dedicated to advancing precision oncology in Asia, is excited to announce the publication of a pioneering real-world study in JCO Oncology Advances, validating circulating tumor DNA (ctDNA) as a strong prognostic biomarker to effectively monitor patients during cancer management.

SINGAPORE, March 26, 2025 /PRNewswire/ -- Gene Solutions, a leading biotech company in Asia, proudly announces a groundbreaking achievement in cancer early detection. The company's innovative SPOT-MAS test has become the first multi-cancer screening blood test in Asia to complete large prospective cohort validation, as published in BMC Medicine. This milestone marks a major advancement, enabling large-scale, non-invasive early detection.

SINGAPORE, Feb. 5, 2025 /PRNewswire/ -- Asia is the region most impacted by lung cancer, accounting for 63.1% of newly diagnosed lung cancers and 62.9% of lung cancer deaths worldwide(1).

SINGAPORE – Media OutReach Newswire - 30 December 2024 – Gene Solutions, a pioneering biotech company in Asia, announced that Bui Que Tran Nguyen, a young scientist from its cancer vaccines R&D team

HO CHI MINH, VIETNAM - Media OutReach Newswire - 9 August 2024 - Gene Solutions, a pioneering genetic testing company in South-East Asia, is excited to announce the publication of a new peer-reviewed study that validates the analytical capabilities of its innovative, AI-driven Tumor-Specific Methylation Atlas (TSMA). The study, published in BMC Journal of Translational Medicine: "Tissue of origin detection (TOO) for cancer tumor using low-depth cfDNA samples through combination of tumor-specific methylation atlas and genome-wide methylation density in graph convolutional neural networks", details the robust analytical validation process which leverages advanced artificial intelligence to deliver precise and reliable tumor origin predictions in multi-cancer early detection.

KUALA LUMPUR, Malaysia, July 1, 2024 /PRNewswire/ -- National Cancer Society Malaysia (NCSM) and Gene Solutions are pleased to announce the signing of a Memorandum of Understanding (MOU) to collaborate on expanding awareness and enabling access to multi-cancer early detection (MCED) testing for the Malaysian population. This landmark partnership was inked at the inaugural National Cancer Congress Malaysia 2024 and aims to revolutionize cancer detection and improve early diagnosis rates across the nation.

HO CHI MINH CITY, Vietnam, April 25, 2023 /PRNewswire/ -- In January 2023, Vietnam's Medical Genetics Institute & Gene Solutions published their research paper on Cancer Investigation: Clinical validation of a ctDNA-based assay for multi-cancer detection: an interim report from a Vietnamese longitudinal prospective cohort study of 2,795 participants.

Gene Solutions, which bills itself as Vietnam’s largest genetic testing company, has raised US$21 million in a series B round from Mekong Capital. This follows a US$15 million investment that the private equity investor made in the company in 2021.

SINGAPORE, March 19, 2024 /PRNewswire/ -- Gene Solutions announced a multi-centre research collaboration with leading OBGYN centres in Vietnam, Singapore, Indonesia, and Philippines on the early prediction of pregnancy complications. This clinical study involving >10,000 women would be the first of its kind, focusing on maternal health, enabling earlier prediction of potential pregnancy complications.